Get 15% OFF on all 2025 Global Market Reports until March 31st! Apply code FY25SAVE and grab your savings today!

How has the genomic biomarker market size evolved in recent years?

The market size for genomic biomarkers has seen substantial growth lately. It is projected to surge from $8.4 billion in 2024 to $9.9 billion in 2025, maintaining a compound annual growth rate (CAGR) of 18.0%. Factors influencing the growth during the historic period include increased understanding of genetic disorders, heightened demand for tailored therapies, advancements in the use of big data in genomics, the development of global genomic databases, and an upsurge in biomarker-based clinical trials.

What are the predictions for the genomic biomarker market size in the coming years?

Expectations are high for the genomic biomarker market to expand significantly in the coming years, increasing to a value of $18.93 billion by 2029. This growth, at a compound annual growth rate (CAGR) of 17.6%, can be attributed to several factors. These include an increased emphasis on tailored medications, a rise in cardiovascular disease incidence, an increase in patients dealing with neurological conditions, heightened investment in genomic research, and the growing trend of adopting personalized nutrition. Key trends projected for the period under consideration include advances in technology, the rise of digital health, the use of artificial intelligence and machine learning, and the growing focus on personalized medicine.

Get your genomic biomarker market report here!

https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report

What key factors are fueling the growth of the genomic biomarker market?

The growth of the genomic biomarker market is anticipated to be fueled by the escalating occurrence of chronic illnesses. These long-lasting health issues tend to persist and typically develop at a slow pace. The swell in chronic illnesses can be attributed to an aging population and increasing lifestyle-related diseases such as obesity and diabetes. Genomic biomarkers facilitate the early identification of these diseases and allow for bespoke prevention measures by determining genetic predispositions and customizing interventions. This reactive measure helps to curb disease prevalence by focusing on individuals who are at risk before the disease develops. For example, in September 2023, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, reported that each year 41 million people succumb to chronic diseases worldwide, representing 74% of all deaths. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory illnesses, and 2.0 million from diabetes. Thus, the escalating prevalence of chronic diseases stimulates the expansion of the genomic biomarker market.

How is the global genomic biomarker market divided into key segments?

The genomic biomarker market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users

Subsegments:

1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction

2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp

Who are the key firms paving the way for growth in the genomic biomarker market?

Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.

Which trends are expected to transform the genomic biomarker market?

Leading firms in the genomic biomarker sector are concentrating their efforts on the creation of superior products like sophisticated liquid biopsy assays. These innovations allow the extensive genomic profiling of solid tumors. Liquid biopsy assays are diagnostic evaluations that investigate genetic material, usually circulating tumor DNA (ctDNA), from a blood specimen to recognize and track cancer. Understanding genomic biomarkers can yield data on specific mutations, gene expression outlines, or other genetic modifications linked to cancer. For instance, in November 2023, the American biotech company Illumina Inc., introduced an advanced liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). This state-of-the-art product expedites the genomic profiling of solid tumors and escalates analytical sensitivity by identifying low-frequency variations with a mere 20 ng of cell-free DNA, a decrease from 30 ng. This results in under four days, considerably quicker than conventional procedures. This optimized approach and imminent automation should facilitate lab incorporation and surge productivity.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20557

What regions are contributing significantly to the growth of the genomic biomarker market?

North America was the largest region in the genomic biomarker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Cancer Biomarker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: